Insider · CIK 0001937573
Thomas Zindrick
ceopresidentofficerdirector
Files at GNLX (GENELUX Corp). First filing Dec 18, 2024, latest Sep 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $232k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GNLX: GENELUX Corp
GNLXOct 9, 2026 · close 2.56
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 49Moderate | GENELUX Corp | $92k 34,463 shares | -3% | - | |
| 40Moderate | GENELUX Corp | $8,668 3,582 shares | -1% | +16% from low-71% from high | |
| 48Moderate | GENELUX Corp | $66k 17,182 shares | -3% | +74% from low-39% from high | |
| 45Moderate | GENELUX Corp | $31k 10,764 shares | -5% | +40% from low-51% from high | |
| 56Moderate | GENELUX Corp | $33k 14,315 shares | -28% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -34,463 | $2.67 | $92k | 1,226,427 | 40 d ago |
| Mar 24, 2026 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -3,582 | $2.42 | $8,668 | 534,849 | Mar 26, 2026 |
| Aug 21, 2025 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -12,673 | $3.33 | $42k | 542,940 | Dec 11, 2025 |
| Nov 17, 2025 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -4,509 | $5.37 | $24k | 538,431 | Dec 11, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -925,000 | - | - | 0 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | AGrant or award Stock Option (Right to Buy)derivative | +925,000 | - | - | 925,000 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -157,372 | - | - | 0 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | AGrant or award Stock Option (Right to Buy)derivative | +157,372 | - | - | 157,372 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -23,568 | - | - | 0 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | AGrant or award Stock Option (Right to Buy)derivative | +23,568 | - | - | 23,568 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -250,000 | - | - | 0 | Sep 3, 2025 |
| Sep 1, 2025 | GNLX GENELUX Corp | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | - | - | 250,000 | Sep 3, 2025 |
| Aug 27, 2025 | GNLX GENELUX Corp | AGrant or award Common Stock | +361,200 | $0.00 | $0 | 554,161 | Aug 29, 2025 |
| Aug 27, 2025 | GNLX GENELUX Corp | AGrant or award Stock Option (Right to Buy)derivative | +478,800 | $0.00 | $0 | 478,800 | Aug 29, 2025 |
| May 12, 2025 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -10,764 | $2.92 | $31k | 191,447 | May 13, 2025 |
| Mar 14, 2025 | GNLX GENELUX Corp | AGrant or award Common Stock | +30,339 | $0.00 | $0 | 202,211 | Apr 17, 2025 |
| Dec 18, 2024 | GNLX GENELUX Corp | AGrant or award Common Stock | +134,500 | $0.00 | $0 | 171,872 | Dec 20, 2024 |
| Dec 18, 2024 | GNLX GENELUX Corp | AGrant or award Stock Option (right to buy)derivative | +183,000 | $0.00 | $0 | 183,000 | Dec 20, 2024 |
| Dec 16, 2024 | GNLX GENELUX Corp | SOpen-market sale Common Stock | -14,315 | $2.34 | $33k | 37,372 | Dec 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.